A Phase 3 interventional study of UT-15C SR and Placebo in Pulmonary Hypertension, sponsored by United Therapeutics. Completed at 62 sites in 12 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2013-01-15.
Sponsored by United Therapeutics · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies testing treprostinil in Hypertension, Pulmonary — 4 open to participants now, 4 under way, 1 of them phase 3. treprostinil · Hypertension, Pulmonary.
Among the 38 studies testing treprostinil in Hypertension, Pulmonary, this one is the 6th largest by enrollment of the 37 interventional ones that give a count, is one of 4 that started in 2009, is one of 15 in phase 3, and was the 12th registered.
1,092 studies on the registry are indexed under Hypertension, Pulmonary; 244 are open to participants now.
Browse Hypertension, Pulmonary studies →4 of the 38 studies testing treprostinil in Hypertension, Pulmonary are open now, in 12 countries. Recruiting first, the newest first:
Valley Health System · Sites in United States
Ages 18+
Liquidia Technologies, Inc. · Sites in United States, Australia, Austria and 9 more countries
Ages 18–80
Magdi H. Yacoub · Sites in Egypt
Ages 18+
University of California, San Diego
Ages 18+
By country, each count listing its studies:
treprostinil: first FDA approval 2002 (REMODULIN), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 164 Hypertension, Pulmonary studies recruiting now, 99 (60%) set no upper age limit and 26 (16%) stop at 75 or younger; 39 take children under 18; 24 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 9 · Phase 3 17 · Phase 4 9
First in 1998; this study’s year is marked. 4 started in 2009.
This study's enrollment of 310 is above the median of 35 across 650 interventional studies indexed under Hypertension, Pulmonary.
Median enrollment 32 across the 37 interventional studies. Of the 29 that completed or were terminated, 19 (66%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 38 have an industry lead sponsor. The 10 most frequent:
United Therapeutics is the lead sponsor of 85 studies on the registry; 8 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 15 (88%) have results posted.
36 studies in Hypertension, Pulmonary by United Therapeutics: 4 open now, 4 under way, 2 of them phase 3. Of 28 finished, 21 (75%) have results posted.
Among the 36 studies in Hypertension, Pulmonary by United Therapeutics, this one is the 8th largest by enrollment of the 31 interventional ones that give a count, is one of 3 that started in 2009, is one of 16 in phase 3, and was the 12th registered.
United Therapeutics’s Hypertension, Pulmonary studies by the year they started, since 1998.
1 of the studies testing treprostinil in Hypertension, Pulmonary that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07116681University of California, San DiegoEffects of Inhaled Treprostinil on Exercise Performance in Exercise Induced Pulmonary Hypertension | 2027-07-01 |
Add it to your calendar (.ics) → With an account.
Among the 38 studies testing treprostinil in Hypertension, Pulmonary, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among United Therapeutics’s 36 in Hypertension, Pulmonary:
This tab as a report to print or save as PDF → With an account.
This study is an international, multi-center, randomized, double-blind, placebo-controlled study in subjects with PAH who are currently receiving approved therapy for their PAH (i.e., endothelin receptor antagonist and/or phosphodiesterase-5 inhibitor). Study visits will occur at 4 week intervals for 16 weeks with the key measure of efficacy being the 6-minute walk test. Study procedures include routine blood tests, medical history, physical exams, disease evaluation, and exercise tests.
Patients who complete all assessments for 16-weeks will also be eligible to enter an open-label, extension phase study (FREEDOM - EXT).
Inclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Identical placebo tablets to UT-15C, doses were titrated in the same manner
Drug: Placebo
Doses were initiated at 0.25 mg BID and increased by 0.25 mg BID every three days (as clinically indicated based on tolerability and symptoms of PAH), to a max dose of 16 mg BID.
Drug: UT-15C SR
treprostinil diolamine sustained release tablets
Also known as: treprostinil diolamine, treprostinil diethanolamine, UT-15C
6-minute Walk Distance (6MWD)
Placebo-corrected change in 6MWD from Baseline to Week 16, correlates with the current clinical standard for assessing patient functional status in the treatment of PAH and is considered an objective measure of patient functional status by the American Thoracic Society (ATS). The 6MWD was to be assessed between 3 and 6 hours after the morning dose of study drug and background therapy(ies).
Time frame: Baseline and 16 weeks
Clinical Worsening Assessment
Definition of clinical worsening included patients who met at least one of the following criteria during the 16 weeks of study: 1. Death (all causes excluding accident) 2. Transplantation 3. Atrial septostomy 4. Hospitalization as a result of right heart failure 5. Greater than or equal to a 20% decrease in 6MWD from Baseline (or too ill to walk) AND addition of an inhaled prostacyclin analogue, ERA, or PDE-5i 6. Initiation of parenteral prostacyclin therapy (i.e., epoprostenol, iloprost, or treprostinil) for the treatment of PAH
Time frame: Baseline and 16 Weeks
Borg Dyspnea Score
The Borg dyspnea score is a 10-point scale rating the maximum level of dyspnea experienced during the six-minute walk test (6MWT). The Borg dyspnea score was assessed immediately following the 6MWT. Scores ranged from 0 (for no shortness of breath) to 10 (for the greatest shortness of breath ever experienced).
Time frame: Baseline and 16 Weeks
World Health Organization (WHO) Functional Class
Class I: No limitation of physical activity. Class II: Slight limitation of physical activity. Class III: Marked limitation of physical activity. Class IV: Inability to carry out any physical activity without symptoms.
Time frame: Baseline and 16 Weeks
Symptoms of PAH
Symptoms of PAH including fatigue, dyspnea, edema, dizziness, syncope, chest pain and orthopnea were assessed by the physician at Baseline and Week 16. Severity grade values (i.e., 0, 1, 2 or 3) for each symptom were provided each subject. A severity of 0 indicated no symptoms, the maximum severity was 3, indicating severe symptoms. Mean change in symptom severity from Baseline to Week 16 is described.
Time frame: Baseline and 16 Weeks
Dyspnea Fatigue Index
The dyspnea-fatigue index was assessed at Baseline and Week 16. Each of the three components of the dyspnea-fatigue index were rated on a scale 0 to 4, with 0 being the worst condition and 4 being the best condition for each component. The dyspnea-fatigue index is computed by summing the three component scores.
Time frame: Baseline and 16 Weeks
N-terminal proBNP (NT-proBNP)
Serum N-terminal pro-BNP concentration was assessed at Baseline and Week 16.
Time frame: Baseline and 16 Weeks
Quality of Life (QoL) Assessment: Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR)
Change in CAMPHOR Scores from Baseline to Week 16. The CAMPHOR is a health related quality of life instrument validated for pulmonary hypertension that assesses impairment (symptoms), disability (activities) and quality of life. The questionnaire is divided into three sections; Symptoms (Scores 0-25; high scores indicate more symptoms), Activity (Score 0-30; low score indicates good functioning)and Quality of Life (0-25; high scores indicate poor QoL). The sum of these scores equates to the Total score (0-80). In the CAMPHOR scores, lower scores indicate improvements.
Time frame: Baseline and 16 Weeks
The recruitment period for this study was June 2009 to July 2011. Sites were located in North America, Europe and Asia.
| Milestone | UT-15C SR | Placebo |
|---|---|---|
| Started | 157 | 153 |
| Completed | 132 | 138 |
| Not completed | 25 | 15 |
| Withdrew: Adverse event | 18 | 5 |
| Withdrew: Clinical worsening | 4 | 4 |
| Withdrew: Death | 2 | 3 |
| Withdrew: Withdrawal by subject | 1 | 2 |
| Withdrew: Lost to follow-up | 0 | 1 |
Placebo-corrected change in 6MWD from Baseline to Week 16, correlates with the current clinical standard for assessing patient functional status in the treatment of PAH and is considered an objective measure of patient functional status by the American Thoracic Society (ATS). The 6MWD was to be assessed between 3 and 6 hours after the morning dose of study drug and background therapy(ies).
| meters | UT-15C SR | Placebo |
|---|---|---|
| Week 16 Values | 370 (292 to 419) | 365 (300 to 405) |
| Change from Baseline | 15 (-12 to 55) | 11 (-14 to 39) |
Definition of clinical worsening included patients who met at least one of the following criteria during the 16 weeks of study: 1. Death (all causes excluding accident) 2. Transplantation 3. Atrial septostomy 4. Hospitalization as a result of right heart failure 5. Greater than or equal to a 20% decrease in 6MWD from Baseline (or too ill to walk) AND addition of an inhaled prostacyclin analogue, ERA, or PDE-5i 6. Initiation of parenteral prostacyclin therapy (i.e., epoprostenol, iloprost, or treprostinil) for the treatment of PAH
| number of clinical worsening events | UT-15C SR | Placebo |
|---|---|---|
| Clinical Worsening Assessment | 11 | 10 |
The Borg dyspnea score is a 10-point scale rating the maximum level of dyspnea experienced during the six-minute walk test (6MWT). The Borg dyspnea score was assessed immediately following the 6MWT. Scores ranged from 0 (for no shortness of breath) to 10 (for the greatest shortness of breath ever experienced).
| score | UT-15C SR | Placebo |
|---|---|---|
| Week 16 Value | 3.0 ± 2.47 | 4.0 ± 2.05 |
| Change from Baseline | 0 (-1.0 to 1.0) | 0 (-1.0 to 1.0) |
Class I: No limitation of physical activity. Class II: Slight limitation of physical activity. Class III: Marked limitation of physical activity. Class IV: Inability to carry out any physical activity without symptoms.
| participants | UT-15C SR | Placebo |
|---|---|---|
| WHO Class I | 1 | 3 |
| WHO Class II | 58 | 47 |
| WHO Class III | 70 | 83 |
| WHO Class IV | 2 | 3 |
Symptoms of PAH including fatigue, dyspnea, edema, dizziness, syncope, chest pain and orthopnea were assessed by the physician at Baseline and Week 16. Severity grade values (i.e., 0, 1, 2 or 3) for each symptom were provided each subject. A severity of 0 indicated no symptoms, the maximum severity was 3, indicating severe symptoms. Mean change in symptom severity from Baseline to Week 16 is described.
| units on a scale | UT-15C SR | Placebo |
|---|---|---|
| Change in Fatigue Symptoms | 0.0 ± 0.9 | 0.0 ± 1.0 |
| Change in Dyspnea Symptoms | -0.1 ± 0.9 | -0.2 ± 0.9 |
| Change in Edema Symptoms | 0.0 ± 1.0 | 0.0 ± 0.9 |
| Change in Dizziness Symptoms | 0.1 ± 1.0 | 0.0 ± 1.0 |
| Change in Syncope Symptoms | 0.2 ± 0.8 | 0.2 ± 0.7 |
| Change in Chest Pain Symptoms | 0.1 ± 1.0 | 0.1 ± 1.0 |
| Change in Orthopnea Symptoms | 0.2 ± 1.0 | 0.1 ± 0.9 |
The dyspnea-fatigue index was assessed at Baseline and Week 16. Each of the three components of the dyspnea-fatigue index were rated on a scale 0 to 4, with 0 being the worst condition and 4 being the best condition for each component. The dyspnea-fatigue index is computed by summing the three component scores.
| units on a scale | UT-15C SR | Placebo |
|---|---|---|
| Dyspnea Fatigue Index | 5.7 ± 2.6 | 6.0 ± 2.5 |
Serum N-terminal pro-BNP concentration was assessed at Baseline and Week 16.
| pg/mL | UT-15C SR | Placebo |
|---|---|---|
| Week 16 Value | 1310 ± 1663 | 1627 ± 2401 |
| Change from Baseline | 135 ± 913 | 136 ± 1242 |
Change in CAMPHOR Scores from Baseline to Week 16. The CAMPHOR is a health related quality of life instrument validated for pulmonary hypertension that assesses impairment (symptoms), disability (activities) and quality of life. The questionnaire is divided into three sections; Symptoms (Scores 0-25; high scores indicate more symptoms), Activity (Score 0-30; low score indicates good functioning)and Quality of Life (0-25; high scores indicate poor QoL). The sum of these scores equates to the Total score (0-80). In the CAMPHOR scores, lower scores indicate improvements.
| units on a scale | UT-15C SR | Placebo |
|---|---|---|
| Symptom Score | 10.0 (6.0 to 16.0) | 9.0 (4.0 to 14.0) |
| Activity Score | 10.0 (7.0 to 14.0) | 10.0 (6.0 to 13.0) |
| Quality of Life Score | 9.0 (4.0 to 15.0) | 5.0 (1.5 to 13.0) |
| Total Score | 28.0 (19.0 to 43.0) | 24.5 (12.0 to 40.5) |
Covariate analysis of change in 6MWD by PAH etiology, specifically idiopathic or heritable PAH
| meters | UT-15C SR | Placebo |
|---|---|---|
| 6-minute Walk Distance by PAH Etiology: Idiopathic PAH (IPAH) / Heritable PAH(HPAH) | 21.5 (-0.5 to 64.5) | 13 (-14 to 39) |
| meters | UT-15C SR | Placebo |
|---|---|---|
| 6-minute Walk Distance by Background PAH Therapy: PDE-5i Only | 30 (4 to 55) | 14 (-7 to 39) |
| meters | UT-15C SR | Placebo |
|---|---|---|
| 6-minute Walk Test by Background PAH Therapy: ERA Only | -5 (-43.0 to 42.0) | -2.5 (-49.0 to 30.0) |
| meters | UT-15C SR | Placebo |
|---|---|---|
| 6-minute Walk Test by Background PAH Therapy: ERA + PDE-5i | 14.0 (-17 to 59) | 15.5 (-14.5 to 39) |
| meters | UT-15C SR | Placebo |
|---|---|---|
| 6-minute Walk Distance by Time to PAH Diagnosis: 0 - 0.9 Years | 21.5 (-12.5 to 50.5) | -6.0 (-63.0 to 26.0) |
| meters | UT-15C SR | Placebo |
|---|---|---|
| 6-minute Walk Distance by Time Since PAH Diagnosis: 0.9 - 1.74 Years | 20.1 (1.0 to 61.0) | 13.0 (-2.0 to 45.0) |
| meter | UT-15C SR | Placebo |
|---|---|---|
| 6-minute Walk Distance by Years Since PAH Diagnosis: 1.8 - 3.5 Years | 15.5 (-16.0 to 51.5) | 4.0 (-14.0 to 42.0) |
| meters | UT-15C SR | Placebo |
|---|---|---|
| 6-minute Walk Distance by Time Since PAH Diagnosis: 3.6 - 26.4 Years | 14.0 (-23.0 to 59.0) | 16.0 (-5.0 to 36.0) |
Collected over Adverse events were recorded throughout the 16 week study.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| UT-15C SR | — | 23/157 (14.6%) | 157/157 (100%) |
| Placebo | — | 23/153 (15%) | 136/153 (88.9%) |
| Event | UT-15C SR | Placebo |
|---|---|---|
| Right ventricular failureCardiac disorders | 5/157 | 2/153 |
| Pulmonary hypertensionRespiratory, thoracic and mediastinal disorders | 2/157 | 4/153 |
| DyspneaRespiratory, thoracic and mediastinal disorders | 4/157 | 2/153 |
| Lower respiratory tract infectionInfections and infestations | 3/157 | 0/153 |
| Fluid overloadMetabolism and nutrition disorders | 2/157 | 1/153 |
| PyrexiaGeneral disorders | 2/157 | 1/153 |
| Back painMusculoskeletal and connective tissue disorders | 2/157 | 0/153 |
| FallInjury, poisoning and procedural complications | 2/157 | 0/153 |
| HemoptysisRespiratory, thoracic and mediastinal disorders | 1/157 | 1/153 |
| Sudden deathGeneral disorders | 1/157 | 1/153 |
| Event | UT-15C SR | Placebo |
|---|---|---|
| HeadacheNervous system disorders | 112/157 | 61/153 |
| DiarrheaGastrointestinal disorders | 87/157 | 38/153 |
| NauseaGastrointestinal disorders | 73/157 | 34/153 |
| FlushingVascular disorders | 55/157 | 16/153 |
| Pain in jawMusculoskeletal and connective tissue disorders | 39/157 | 10/153 |
| VomitingGastrointestinal disorders | 33/157 | 16/153 |
| DizzinessNervous system disorders | 30/157 | 15/153 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 27/157 | 11/153 |
| NasopharyngitisRespiratory, thoracic and mediastinal disorders | 17/157 | 25/153 |
| DyspneaRespiratory, thoracic and mediastinal disorders | 25/157 | 10/153 |
| Age, Categorical(Participants) | UT-15C SR | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 119 | 122 | 241 |
| >=65 years | 38 | 31 | 69 |
| Age Continuous(years) | UT-15C SR | Placebo | Total |
|---|---|---|---|
| Mean | 51.5 ± 15 | 50.4 ± 14.5 | 51.0 (18 to 76) |
| Sex: Female, Male(Participants) | UT-15C SR | Placebo | Total |
|---|---|---|---|
| Female | 119 | 122 | 241 |
| Male | 38 | 31 | 69 |
| PAH Etiology(participants) | UT-15C SR | Placebo | Total |
|---|---|---|---|
| Idiopathic or familial | 104 | 99 | 203 |
| Collagen vascular disease | 48 | 49 | 97 |
| HIV infection | 2 | 4 | 6 |
| Repaired congenital heart disease | 3 | 1 | 4 |
| World Health Organization (WHO) Functional Class(Participants) | UT-15C SR | Placebo | Total |
|---|---|---|---|
| Class II | 43 | 37 | 80 |
| Class III | 110 | 115 | 225 |
| Class IV | 3 | 0 | 3 |
| Unknown | 1 | 1 | 2 |
| Baseline Six-minute walk distance(meters) | UT-15C SR | Placebo | Total |
|---|---|---|---|
| Mean | 329.4 ± 69.2 | 336.8 ± 63.5 | 333 ± 66.4 |
| Background PAH therapy(participants) | UT-15C SR | Placebo | Total |
|---|---|---|---|
| PDE-5i | 67 | 65 | 132 |
| ERA | 25 | 28 | 53 |
| PDE-5i + ERA | 65 | 60 | 125 |
| Time since PAH diagnosis(years) | UT-15C SR | Placebo | Total |
|---|---|---|---|
| Mean | 2.5 ± 2.6 | 3.3 ± 4.1 | 2.9 ± 3.4 |
The record gives a start of Jun 2009, a primary completion of Jul 2011 and a completion of Jul 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2013, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Treprostinil